TSLC1 gene silencing in cutaneous melanoma

You, Yan; Ma, Le; You, Min; Li, Xiaomei; Wang, Shuhai; Liu, Hongli; Wu, Debin; Yang, Huimin; Li, Zhen Yu

doi:10.1097/cmr.0b013e32833413c0

Cited by 24 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously, we observed that TSLC1 promoter was methylated in 58 (48.33%) of 120 cutaneous melanomas [7]. As such, the loss or downregulation of TSLC1 in cutaneous melanomas in this study was likely caused by aberrant promoter methyla- Expression in melanomas and nevi You et al 433 tion, which in turn resulted in a loss of TSLC1 function.…”

Section: Discussionmentioning

confidence: 74%

“…We have shown previously that tumor suppressor in lung cancer 1 (TSLC1) is a tumor suppressor gene, and its silencing through aberrant promoter methylation is associated with the generation of cutaneous melanoma [7]. Therefore, in the present study, we examined the expression of tumor suppressor gene TSLC1 in three groups of lesions: cutaneous melanomas, dysplastic nevi lesions, and normal skin samples, and determined whether it could serve as a diagnostic marker in histologically questionable lesions.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi

You

Wang²,

Zhang³

et al. 2012

Melanoma Research

Self Cite

View full text Add to dashboard Cite

Cutaneous melanoma is a malignant tumor of melanocytes that causes the majority of skin cancer-related deaths. However, sometimes, discrimination between dysplastic nevi and early melanomas is difficult, even for experienced pathologists. Besides histology, the silencing of tumor suppressor genes aids in the diagnosis of melanoma. We have shown previously that tumor suppressor in lung cancer 1 (TSLC1) is a tumor suppressor gene, and its silencing through aberrant promoter methylation is associated with the generation of cutaneous melanoma. To examine TSLC1 expression in melanocytic skin lesions to determine whether it can serve as a diagnostic marker in histologically questionable lesions. Cytoplasmic localization of the expression of the TSLC1 gene was detected by immunohistochemistry; the levels of TSLC1 mRNA and protein were detected by quantitative real-time reverse transcription-PCR and western blot, respectively. Using immunohistochemistry, the average TSLC1 expression levels in cutaneous melanomas decreased approximately 3.6-fold (n=20) as compared with dysplastic nevi (n=30) and 3.7-fold as compared with normal skin (n=25). The average expression levels of TSLC1 mRNA and protein in dysplastic nevi lesions and normal skin were significantly higher than the levels in cutaneous melanomas. No significant changes in TSLC1 mRNA and protein expressions were found between normal skin and dysplastic nevi. Our results show that a loss of TSLC1 frequently occurs in cutaneous melanoma, and indicate that it could serve as a diagnostic marker for cutaneous melanoma in histologically questionable lesions.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Introductionmentioning

confidence: 98%

TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi

You

Wang²,

Zhang³

et al. 2012

Melanoma Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…Epigenetic inactivation of tumor suppressor genes has been implicated in tumorigenesis and progression of a variety of different malignancies [9][10][11], and recent studies are beginning to show the role of epigenetic events in cutaneous melanoma.…”

Section: Introductionmentioning

confidence: 99%

Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays

et al. 2015

View full text Add to dashboard Cite

Aberrant methylation of promoter regions involved in silencing of tumor suppressor genes is a key feature of many human cancers including melanoma. These DNA methylation events occur early in cancer development, increase with progression, and may therefore serve as biomarkers for the detection and staging of cancer. In our study, we used an epigenomic reactivation screening approach including Combined Bisulfite Restriction Analyses (COBRA) assays to identify novel methylation markers in late-stage melanoma. Two human xenograft melanoma models have been used to identify genes methylated in cancer and reactivated upon treatment with a histone deacetylase inhibitor. Gene expression analysis and promoter scanning for DNA methylation by COBRA assays and bisulfite sequencing were used to identify candidate genes. The methylation status of the CpG island promoter region of genes related to melanoma pathophysiology in skin, lymph node, and visceral metastatic metastases in 28 patients (samples n=35) were assessed. These methylation markers have been evaluated in melanoma metastasis tissue and in control samples from normal skin. The screening in in-vitro and in-vivo systems for methylated genes in melanoma samples showed 10 candidate genes. Using COBRA assays, we detected a methylation pattern in the promoter region of 10 genes with two genes (BASP1, CDH11), together with the patient's age and the log-S100B-level at biopsy, constructing a descriptor with a trend to correlate with shorter time to death.

show abstract

“…Up to 100% of melanoma cases show hyper-methylated CYP1B1 (Cytochrome P450, subfamily 1, polypeptide 1, linked to drug metabolism) and QPCT (Glutaminylpeptide cyclotransferase) (Muthusamy et al, 2006). Recently, in cutaneous melanoma the loss of expression/methylation of gene promoter for Tumor suppressor in lung cancer 1 (TSLC1), encoding a member of the immunoglobulin superfamily, has been described (You et al, 2010). In some cancer types, this phenomenon leads to poor prognosis, and in melanoma it is significantly associated with advanced tumor stage and shorter diseaserelated survival, thus appearing as an important event in the pathogenesis of CM and a marker of poor prognosis (You et al, 2010).…”

Section: Wwwintechopencommentioning

confidence: 99%

“…Recently, in cutaneous melanoma the loss of expression/methylation of gene promoter for Tumor suppressor in lung cancer 1 (TSLC1), encoding a member of the immunoglobulin superfamily, has been described (You et al, 2010). In some cancer types, this phenomenon leads to poor prognosis, and in melanoma it is significantly associated with advanced tumor stage and shorter diseaserelated survival, thus appearing as an important event in the pathogenesis of CM and a marker of poor prognosis (You et al, 2010). Similarly, recent findings indicated that a frequently aberrant methylated region in CM resides within the Zygote arrest 1 (ZAR1) gene, demonstrating a distinct methylation pattern between melanoma and nevus, thus hypothesizing that the aberrant methylation of ZAR1 may be a useful tumor biomarker to distinguish nevus from melanoma for early diagnosis (Shinojima et al, 2010).…”

Section: Wwwintechopencommentioning

confidence: 99%